Tafasitamab sold to IncyteNovartis to launch a voluntary public takeover offer for all MorphoSys shares at a price of € 68.00 per share in cashShareholders benefit from attractive premium of 94 percent to the one-month volume weighted average price before January 25, 2024Novartis provides ample resources to maximize.
Germany - MorphoSys AG today announced the company entered into a Business Combination Agreement with Novartis data42 AG and Novartis AG based on Novartis intention to submit a voluntary public.
EQS-News: MorphoSys AG / Key word: Forecast
MorphoSys Reports Preliminary 2023 Monjuvi U.S. Net Product Sales and Gross Margin, Provides 2024 Financial Guidance and Reduces.
MorphoSys AG / Key word(s): ForecastAd hoc: MorphoSys AG Reports Preliminary 2023 Monjuvi U.S. Net Product Sales and Gross Margin, Provides 2024 Financial Guidance and Reduces Financial Liability30-Jan-2024 / 08:47 CET/CESTDisclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014,.
MorphoSys Reports Preliminary 2023 Monjuvi U S Net Product Sales and Gross Margin, Provides 2024 Financial Guidance and Reduces Financial Liability streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.